View Clinical Trial (Medical Research Study)
Comparison of the Effects of LY2605541 and Insulin Glargine on Endogenous Glucose Output and Peripheral Glucose Disposal in Healthy Subjects and Patients With Type 1 Diabetes Mellitus
| City: |
|
San Diego |
| State: |
|
California |
| Zip Code: |
|
|
| Conditions: |
|
Healthy Volunteers - Diabetes Mellitus, Type 1 |
| Purpose: |
|
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus.
This study is designed to understand how the body handles the investigational drug, what
effect this investigational drug has on the body and how much should be given. This study
will also measure how much of the investigational drug gets into the blood stream and how
long it takes the body to get rid of it. The study has 2 parts: Part A will be conducted in
healthy participants. Part B will be conducted in participants with type 1 diabetes mellitus
(T1DM). This study will take approximately 10-14 days spread over 6-20 weeks, not including
screening. Screening will be performed within 30 days of the start of the study.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
All Participants
- Are healthy males or participants with T1DM
- Have a screening body mass index (BMI) of 20.0-29.9 kilograms per square meter
(kg/m^2)
Healthy Participants ONLY
- Are overtly healthy, as determined by medical history and physical examination
- Have a fasting blood glucose <108 milligrams/deciliter (mg/dL) (6.0 millimoles/liter
[mmol/L]) at screening
Participants with T1DM ONLY
- Have a diagnosis of T1DM for at least 1 year based on medical history
- Have a screening c-peptide <0.5 nanogram/milliliter (ng/mL)
- Have a hemoglobin A1c (HbA1c) of 6.0 to 9.0% at screening
- Have had no episodes of severe hypoglycemia in the past 6 months (severe hypoglycemia
is defined as having neurological symptoms consistent with neuroglycopenia and having
required assistance in treatment by a second party)
Exclusion Criteria:
All Participants
- Have a hemoglobin level <12.0 grams/deciliter (g/dL) at screening
- Is currently a smoker or used tobacco products on a regular basis in the 6 months
prior to screening, or intending to smoke during the study
Healthy Participants ONLY
• Regular use or intended use of over-the counter or prescription medication within 7 and
14 days, respectively, prior to dosing (apart from vitamin/mineral supplements or
occasional use of acetaminophen or ibuprofen). If this situation arises, inclusion of an
otherwise suitable participants may be at the discretion of the investigator
Participants with T1DM ONLY
- Regular use or intended use of any over-the-counter or prescription medications or
nutritional supplements that affect blood glucose or the body's sensitivity to
insulin or that promote weight loss within 14 days prior to dosing
- Are receiving chronic (lasting longer than 14 consecutive days) systemic or inhaled
glucocorticoid therapy (excluding topical, intra-articular, and intraocular
preparations) or have received such therapy within the 4 weeks before dosing
- Require a total daily insulin dose exceeding 100 units (U)
- Have fasting triglycerides >400 mg/dL
|
| NCT ID: |
|
NCT01654380 |
| Primary Contact: |
|
Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone: 1-317-615-4559
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
San Diego, California
United States
Eli Lilly
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 17, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|